R&D News | pharmaphorum

News

BMS’ LAG-3 RELATIVITY theory fails futility test

Bristol-Myers Squibb has abandoned a bid to extend the indications of its combination of PD-1 inhibitor Opdivo and LAG-3 inhibitor relatlimab into colorectal cancer after

News

Enrolment starts in trial of AI-powered Parkinson’s therapy

Patient recruitment is now underway in a clinical trial of Newel Health’s digital therapeutic for Parkinson’s disease, which hopes to show it can enhance the efficacy of t

News

MSD, Moderna cancer vaccine aces melanoma study

MSD and Moderna’s individualised cancer vaccine mRNA-4157 has shown impressive efficacy in a phase 2b trial in skin cancer melanoma.

News

MindMed says LSD-based therapy effective in anxiety

Psychedelic medicines specialist MindMed has said that its LSD-based treatment MM-120 has shown efficacy in a proof-of-concept study involving patients with generalised an

News

Pharnext hit again as rare disease drug flunks phase 3 test

French biotech Pharnext has seen the value of its shares collapse after it revealed that its lead drug, a treatment for Charcot-Marie-Tooth (CMT) disease, failed to make t

News

Daiichi Sankyo taps Depixus to speed RNA drug discovery

Daiichi Sankyo has made the development of RNA-based therapeutics and vaccines one of the pillars of its R&D operations and has turned to start-up Depixus to accelerat

BMS’ LAG-3 RELATIVITY theory fails futility test

Enrolment starts in trial of AI-powered Parkinson’s therapy

MSD, Moderna cancer vaccine aces melanoma study

MindMed says LSD-based therapy effective in anxiety

Pharnext hit again as rare disease drug flunks phase 3 test

Daiichi Sankyo taps Depixus to speed RNA drug discovery

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks